3401 Technology Dr.
110 articles with Astellas Pharma
12/12/2017Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its "Throttle" technology.
Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia
The data are being presented today in an oral presentation at the 2017 ASH Annual Meeting.
Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013.
Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients at the 2017 ASH
The wide selection of abstracts showcases the company’s full-scale development program across the FLT3 mutation-positive AML care continuum-from newly-diagnosed to relapsed or refractory patients.
MindBytes BVBA Initiates Oncology R&D Program Focused on Patient Empowerment and is Selected as One of Five Finalists for Astellas Oncology C3 Prize
MindBytes believes these tools can empower patients and play an important role in addressing ongoing challenges in cancer care.
Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) designed to deliver the cell-killing agent monomethyl auristatin E (MMAE) to the target Nectin-4.
Astellas and Seattle Genetics Initiate Phase Ib Trial of Enfortumab Vedotin in Combination With Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
Enfortumab vedotin is an investigational ADC designed to deliver the cell-killing agent MMAE to the target Nectin-4.
Sales in the first six months of FY2017 decreased by 1.8% compared to those in the corresponding period of the previous fiscal year (“year-on-year”) to JPY639.8 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.
Strong Cresemba (Isavuconazole) Sales in The United States Trigger First Sales Milestone Payment to Basilea
Under the agreement, Basilea is still eligible for additional sales milestone payments of up to CHF 285 million in addition to tiered, double-digit royalties on U.S. sales.
Universal Cells will get $9 million upfront and is eligible to regulatory milestones payments of up to $115 million, as well as royalties.